soul trial oral semaglutide cardiovascular outcomes 2025 results The SOUL Trial soul semaglutide trial oral cardiovascular

The presence of an MTHFR polymorphism should therefore be viewed as one factor influencing methylation efficiency rather than evidence that folic acid is ineffective

By month 4 (week 16), over 85% of patients report minimal to no side effects

How Should I Use Zepbound

The Triple-Agonist Breakthrough Retatrutide (LY3437943), developed by Eli Lilly, is an investigational triple-agonist peptide that activates three metabolic receptors simultaneously: GLP-1, GIP, and the glucagon receptor

Evidencebased education Learn portion control, label reading and nutrient timing

Start with the simplest interventions and escalate if needed